Security
Novavax, Inc. Common Stock · NVAX
NVAXNASDAQCommon stockCurrentCIK 1000694Updated Oct 30, 2026
NVAX price & chart
Loading TradingView…
NASDAQ:NVAX on TradingView ↗About the company
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient R&D innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information.
In the news
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 News provided by Novavax, Inc. Oct 30, 2025, 08:00 ET Share this article Share to X Share this article Share to X GAITHERSBURG, Md. , Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX ) today announced it will report ↗
Seeking Alpha
Tough Trading Leaves Indices In The Red ↗
Novavax: Sell The False Plague Breakout ↗
Novavax: Vaccine Maker Sees Momentum In 2026, But Growth Story Holds Fundamental Risks ↗
SEC disclosures
NOVAVAX INC files 8-K: Material Event ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
S-8 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,179,889,000Source | 1,712,483,000Source | 955,575,000Source | 1,336,549,000Source | 1,818,646,000Source | 1,043,162,000Source | 1,292,992,000Source | 1,353,534,000Source | 1,176,512,000Source | 1,560,418,000Source | 1,797,490,000Source | 2,258,679,000Source |
| Property, Plant and Equipment, NetUSD | 49,120,000Source | 285,724,000Source | 38,133,000Source | 129,643,000Source | 288,559,000Source | 42,149,000Source | 133,538,000Source | 291,093,000Source | 44,800,000Source | 138,413,000Source | 305,771,000Source | 294,247,000Source |
| GoodwillUSD | 113,080,000Source | 126,766,000Source | 112,542,000Source | 112,958,000Source | 123,377,000Source | 112,888,000Source | 112,027,000Source | 123,179,000Source | 113,462,000Source | 107,478,000Source | 127,454,000Source | 126,331,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 268,023,000Source | 573,630,000Source | 191,458,000Source | 253,744,000Source | 680,162,000Source | 228,363,000Source | 263,338,000Source | 480,586,000Source | 240,634,000Source | 530,230,000Source | 568,505,000Source | 1,336,883,000Source |
| Accounts Receivable | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Inventory, NetUSD | 13,511,000Source | 8,638,000Source | 10,006,000Source | 10,240,000Source | 9,172,000Source | 11,458,000Source | 10,263,000Source | 15,778,000Source | 11,545,000Source | 8,749,000Source | 41,696,000Source | 36,683,000Source |
| Assets, CurrentUSD | 974,590,000Source | 1,103,680,000Source | 771,098,000Source | 919,512,000Source | 1,203,370,000Source | 850,816,000Source | 868,028,000Source | 727,120,000Source | 978,276,000Source | 1,128,942,000Source | 1,143,888,000Source | 1,703,391,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 45,532,000Source | 80,002,000Source | 23,013,000Source | 59,823,000Source | 102,013,000Source | 25,714,000Source | 71,095,000Source | 198,921,000Source | 26,815,000Source | 78,164,000Source | 226,023,000Source | 237,147,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 131,000,000Source | — | — | 134,000,000Source | — | 20,332,000Source | 21,846,000Source | 24,985,000Source | 36,384,000Source |
| Other Assets, NoncurrentUSD | 19,226,000Source | 30,547,000Source | 13,960,000Source | 21,392,000Source | 33,833,000Source | 15,951,000Source | 21,904,000Source | 30,967,000Source | 17,077,000Source | 24,000,000Source | 35,159,000Source | 28,469,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,336,561,000Source | 2,238,919,000Source | 1,146,282,000Source | 1,298,924,000Source | 2,250,352,000Source | 1,187,924,000Source | 1,368,635,000Source | 2,220,618,000Source | 1,304,265,000Source | 2,184,259,000Source | 2,514,417,000Source | 2,892,757,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,648,000Source | 1,616,000Source | 1,682,000Source | 1,645,000Source | 1,613,000Source | 1,678,000Source | 1,642,000Source | 1,417,000Source | 1,650,000Source | 1,619,000Source | 1,405,000Source | 868,000Source |
| Additional Paid in CapitalUSD | 4,531,763,000Source | 4,490,630,000Source | 4,558,457,000Source | 4,522,193,000Source | 4,477,748,000Source | 4,548,592,000Source | 4,512,849,000Source | 4,204,775,000Source | 4,539,756,000Source | 4,501,403,000Source | 4,192,164,000Source | 3,737,979,000Source |
| Retained Earnings (Accumulated Deficit)USD | -4,585,675,000Source | -4,927,420,000Source | -4,631,026,000Source | -4,383,296,000Source | -4,806,120,000Source | -4,577,639,000Source | -4,489,804,000Source | -4,968,501,000Source | -4,568,148,000Source | -5,008,450,000Source | -4,820,951,000Source | -4,275,889,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,745,000Source | 3,598,000Source | -7,448,000Source | -458,000Source | -10,508,000Source | -5,074,000Source | 1,608,000Source | -10,825,000Source | 2,010,000Source | -22,559,000Source | 2,722,000Source | -6,377,000Source |
| Stockholders' Equity Attributable to ParentUSD | -156,672,000Source | -526,436,000Source | -190,707,000Source | 37,625,000Source | -431,706,000Source | -144,762,000Source | -75,643,000Source | -867,084,000Source | -127,753,000Source | -623,841,000Source | -716,927,000Source | -634,078,000Source |
| Liabilities and EquityUSD | 1,179,889,000Source | 1,712,483,000Source | 955,575,000Source | 1,336,549,000Source | 1,818,646,000Source | 1,043,162,000Source | 1,292,992,000Source | 1,353,534,000Source | 1,176,512,000Source | 1,560,418,000Source | 1,797,490,000Source | 2,258,679,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 429,869,000Source | 1,180,999,000Source | 330,574,000Source | 389,138,000Source | 1,157,811,000Source | 342,461,000Source | 422,170,000Source | 804,382,000Source | 459,950,000Source | 1,154,416,000Source | 1,635,138,000Source | 2,459,944,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 9,878,000Source | 10,094,000Source | 22,977,000Source | 16,867,000Source |
| Accounts Payable, CurrentUSD | 15,227,000Source | 57,517,000Source | 22,936,000Source | 50,595,000Source | 79,962,000Source | 16,101,000Source | 34,162,000Source | 57,724,000Source | 24,578,000Source | 41,579,000Source | 132,610,000Source | 216,517,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | 19,359,000Source | 22,958,000Source | 28,577,000Source | 50,085,000Source |
| Other Liabilities, NoncurrentUSD | 263,483,000Source | 318,917,000Source | 165,744,000Source | 287,585,000Source | 335,292,000Source | 193,244,000Source | 313,727,000Source | 351,722,000Source | 239,068,000Source | 359,614,000Source | 33,130,000Source | 55,695,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 115,586,000Source | 218,674,000Source | 81,424,000Source | 86,697,000Source | 159,221,000Source | 103,027,000Source | 132,165,000Source | 257,365,000Source | 107,165,000Source | 211,165,000Source | 394,668,000Source | 591,158,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 455,000Source | 402,000Source | 2,043,000Source | — |
| Long-term Debt | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 3,062,000Source | 8,340,000Source | 28,000,000Source | 48,000,000Source | 41,000,000Source | 29,100,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 7,724,000Source | 10,285,000Source | 36,015,000Source | 48,152,000Source | 85,357,000Source | 130,300,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 226,000Source | -2,375,000Source | 3,240,000Source | -12,914,000Source | 74,457,000Source | 477,801,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -32,423,000Source | -185,502,000Source | -244,635,000Source | -87,263,000Source | -713,967,000Source | -415,937,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -28,361,000Source | -73,319,000Source | -78,267,000Source | -204,038,000Source | -58,806,000Source | -92,985,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 37,675,000Source | -7,061,000Source | 27,737,000Source | 260,583,000Source | 4,466,000Source | 324,988,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -23,127,000Source | -266,812,000Source | -289,240,000Source | -38,518,000Source | -765,035,000Source | -179,414,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 283,357,000Source | 588,587,000Source | 196,040,000Source | 268,982,000Source | 232,925,000Source | 278,480,000Source | 256,052,000Source | 545,292,000Source | 583,810,000Source | 1,348,845,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 6,294,000Source | 2,799,000Source | 15,047,000Source | 17,572,000Source | 17,349,000Source | 18,035,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 1,847,000Source | 1,499,000Source | 8,806,000Source | 949,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -18,000Source | -930,000Source | 5,925,000Source | -7,800,000Source | 3,272,000Source | 4,520,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 8,549,000Source | 12,049,000Source | 8,089,000Source | 9,214,000Source | 7,724,000Source | 10,285,000Source | 36,015,000Source | 48,152,000Source | 85,357,000Source | 130,300,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 402,000Source | 416,000Source | — | 442,000Source | — | 442,000Source | 1,660,000Source | 1,668,000Source | 1,689,000Source | 1,497,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | 0Source | 51,949,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -28,714,000Source | 0Source | — | — | — | — | -28,714,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | 70,747,000Source | — | 43,612,000Source | — | 48,090,000Source | — | — | 468,946,000Source | 488,691,000Source |
| GoodwillUSD | — | — | 113,080,000Source | 126,766,000Source | 112,542,000Source | 112,958,000Source | 112,888,000Source | 112,027,000Source | 113,462,000Source | 107,478,000Source | 127,454,000Source | 126,331,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Income Tax Expense (Benefit)USD | — | — | -657,000Source | -1,032,000Source | 1,711,000Source | 946,000Source | 985,000Source | 1,200,000Source | 1,865,000Source | 10,884,000Source | 2,031,000Source | 4,292,000Source |
| InterestExpenseNonoperatingUSD | — | — | 5,482,000Source | 4,236,000Source | 5,689,000Source | 5,518,000Source | 4,901,000Source | 5,723,000Source | 22,547,000Source | 20,075,000Source | — | — |
| Inventory Write-downUSD | — | — | 200,000Source | 1,400,000Source | 1,600,000Source | 1,100,000Source | 0Source | 300,000Source | 1,900,000Source | 21,000,000Source | 72,400,000Source | -79,214,000Source |
| Investment Income, InterestUSD | — | — | 7,200,000Source | 12,300,000Source | 6,900,000Source | 7,000,000Source | 7,100,000Source | 8,000,000Source | 29,500,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -202,379,000Source | -121,300,000Source | -53,387,000Source | 106,508,000Source | -9,491,000Source | 518,646,000Source | 440,302,000Source | -187,499,000Source | -545,062,000Source | -657,939,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -202,379,000Source | -121,300,000Source | -53,387,000Source | 106,508,000Source | -9,491,000Source | 518,646,000Source | 440,302,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 9,178,000Source | 15,922,000Source | 8,919,000Source | 11,902,000Source | 11,825,000Source | 10,056,000Source | 40,633,000Source | 40,442,000Source | 37,896,000Source | 10,969,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 0Source | 263,272,000Source | 360,243,000Source | 249,230,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 147,289,000Source | 43,000,000Source | 353,735,000Source | 443,551,000Source | — | — |
| Impairment of Intangible Assets, Finite-lived | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 70,445,000Source | 84,512,000Source | 56,698,000Source | 239,240,000Source | 139,514,000Source | 666,655,000Source | 1,123,479,000Source | 682,162,000Source | 983,705,000Source | 1,981,872,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 31,655,000Source | 70,747,000Source | 26,665,000Source | 43,612,000Source | 28,777,000Source | 48,090,000Source | 157,479,000Source | 337,185,000Source | — | — |
| Operating Income (Loss)USD | — | — | -178,018,000Source | -134,018,000Source | -54,906,000Source | 101,070,000Source | -15,430,000Source | 515,513,000Source | 452,795,000Source | -248,931,000Source | -566,511,000Source | -644,736,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 9,178,000Source | 15,922,000Source | 8,919,000Source | 11,902,000Source | 11,825,000Source | 10,056,000Source | 40,633,000Source | 40,442,000Source | 37,896,000Source | 10,969,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -203,036,000Source | -122,332,000Source | -51,676,000Source | 107,454,000Source | -8,506,000Source | 519,846,000Source | 442,167,000Source | -176,615,000Source | -543,031,000Source | -653,647,000Source |
| Income Tax Expense (Benefit)USD | — | — | -657,000Source | -1,032,000Source | 1,711,000Source | 946,000Source | 985,000Source | 1,200,000Source | 1,865,000Source | 10,884,000Source | 2,031,000Source | 4,292,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -202,379,000Source | -121,300,000Source | -53,387,000Source | 106,508,000Source | -9,491,000Source | 518,646,000Source | 440,302,000Source | -187,499,000Source | -545,062,000Source | -657,939,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.25Source | -0.76Source | -0.32Source | 0.66Source | -0.06Source | 3.22Source | 2.72Source | -1.23Source | -5.41Source | -8.42Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.25Source | -0.76Source | -0.32Source | 0.62Source | -0.06Source | 2.93Source | 2.58Source | -1.23Source | -5.41Source | -8.42Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 162,353,000Source | 160,049,000Source | 164,574,000Source | 162,019,000Source | 163,276,000Source | 161,049,000Source | 161,991,000Source | 152,190,000Source | 100,768,000Source | 78,183,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 162,353,000Source | 160,049,000Source | 164,574,000Source | 177,215,000Source | 163,276,000Source | 177,625,000Source | 173,103,000Source | 152,190,000Source | 100,768,000Source | 78,183,000Source |
| Interest Expense (non-operating)USD | — | — | 5,482,000Source | 4,236,000Source | 5,689,000Source | 5,518,000Source | 4,901,000Source | 5,723,000Source | 22,547,000Source | 20,075,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 248,463,000Source | 218,530,000Source | 111,604,000Source | 138,170,000Source | 154,944,000Source | 151,142,000Source | 670,684,000Source | 931,093,000Source | 1,550,216,000Source | 2,626,608,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,882,000Source | 12,307,000Source | -12,000Source | 4,292,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 3,062,000Source | 8,340,000Source | 27,613,000Source | 48,496,000Source | 41,225,000Source | 29,054,000Source |
| General and Administrative ExpenseUSD | — | — | — | 70,747,000Source | — | 43,612,000Source | — | 48,090,000Source | — | — | 468,946,000Source | 488,691,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 426,282,000Source | -261,909,000Source | -628,984,000Source | -712,183,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 14,416,000Source | 19,880,000Source |
| Interest Expense, DebtUSD | — | — | 2,956,000Source | 2,608,000Source | 4,547,000Source | 2,634,000Source | 3,742,000Source | 2,634,000Source | 11,527,000Source | 10,430,000Source | 11,468,000Source | 14,039,000Source |
| Investment Income, InterestUSD | — | — | 7,200,000Source | 12,300,000Source | 6,900,000Source | 7,000,000Source | 7,100,000Source | 8,000,000Source | 29,500,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -202,379,000Source | -121,300,000Source | -53,387,000Source | 106,508,000Source | -9,491,000Source | 518,646,000Source | 440,302,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 98,274,000Source | 87,164,000Source | 70,693,000Source | 79,233,000Source | 95,472,000Source | 88,937,000Source | 342,320,000Source | 391,169,000Source | 737,502,000Source | 1,235,278,000Source |
Filing attachments
tm2628546d1_ex99-1.htm · 8-K · 2026-10-29
Exhibit 99.1 News & Media Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe October 29, 2026 The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi …
Read attachment ↗fp0098293-1_ex991.htm · SCHEDULE 13D/A · 2026-04-08
Himanshu H. Shah Managing Partner and Chief Investment Officer SHAH CAPITAL OPPORTUNITY FUND LP April 8, 2026 Board of Directors of Novavax Inc. 21 Firstfield Rd. Gaithersburg, MD 20878 Notice of Intention to VOTE AGAINST Board Nominees and Executive Compensation - Shah Capital Open Letter As a large and long-term 9% shareholder, we are writing to formally notify you of our intent to vote AGAINST the re-election of board nominees and AGAINST the executive compensation package at the u…
Read attachment ↗nvax-20251231xex47.htm · 10-K · 2026-02-26
Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2025, Novavax, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Description of Common Stock The following description of the Company’s Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety b…
Read attachment ↗tm262897d1_ex99-1.htm · 8-K · 2026-01-12
EX-99.1 2 tm262897d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 © 2026 NOVAVAX. All rights reserved. 1 Novavax Corporate Presentation John C. Jacobs, President and Chief Executive Officer J.P. Morgan Healthcare Conference © 2026 NOVAVAX. All rights reserved. 1 © 2026 NOVAVAX. All rights reserved. 2 We envision a world where our technology is amplified to touch the lives of billions, sparking transformation in global health. This is Novavax © 2026 NOVAVAX. All rights…
Read attachment ↗tm2530132d1_ex99-1.htm · 8-K · 2025-11-04
EX-99.1 2 tm2530132d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid™ to Sanofi in line with its CLA and its corporate strategy, securing a total of $225 million in non-dilutive capital year-to-date 2025 GAITHERSBURG, Md., N…
Read attachment ↗tm2528134d1_ex99-1.htm · 8-K · 2025-10-07
EX-99.1 2 tm2528134d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment GAITHERSBURG, Md., October 7, 2025 - Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European Union (EU) enabling Sanofi to take full responsibility for commercial and r…
Read attachment ↗